155 related articles for article (PubMed ID: 28102671)
1. Structural Analysis of the Glycosylated Intact HIV-1 gp120-b12 Antibody Complex Using Hydroxyl Radical Protein Footprinting.
Li X; Grant OC; Ito K; Wallace A; Wang S; Zhao P; Wells L; Lu S; Woods RJ; Sharp JS
Biochemistry; 2017 Feb; 56(7):957-970. PubMed ID: 28102671
[TBL] [Abstract][Full Text] [Related]
2. Structural elements of primary CCR5-using HIV-1 gp120 proteins influencing sensitivity and resistance to the broadly neutralizing monoclonal antibody b12.
Sterjovski J; Churchill MJ; Ellett A; Wesselingh SL; Ramsland PA; Gorry PR
Virology; 2012 Oct; 432(2):394-404. PubMed ID: 22818780
[TBL] [Abstract][Full Text] [Related]
3. Structural basis for germline antibody recognition of HIV-1 immunogens.
Scharf L; West AP; Sievers SA; Chen C; Jiang S; Gao H; Gray MD; McGuire AT; Scheid JF; Nussenzweig MC; Stamatatos L; Bjorkman PJ
Elife; 2016 Mar; 5():. PubMed ID: 26997349
[TBL] [Abstract][Full Text] [Related]
4. Computation-guided backbone grafting of a discontinuous motif onto a protein scaffold.
Azoitei ML; Correia BE; Ban YE; Carrico C; Kalyuzhniy O; Chen L; Schroeter A; Huang PS; McLellan JS; Kwong PD; Baker D; Strong RK; Schief WR
Science; 2011 Oct; 334(6054):373-6. PubMed ID: 22021856
[TBL] [Abstract][Full Text] [Related]
5. Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120.
Kong L; Lee JH; Doores KJ; Murin CD; Julien JP; McBride R; Liu Y; Marozsan A; Cupo A; Klasse PJ; Hoffenberg S; Caulfield M; King CR; Hua Y; Le KM; Khayat R; Deller MC; Clayton T; Tien H; Feizi T; Sanders RW; Paulson JC; Moore JP; Stanfield RL; Burton DR; Ward AB; Wilson IA
Nat Struct Mol Biol; 2013 Jul; 20(7):796-803. PubMed ID: 23708606
[TBL] [Abstract][Full Text] [Related]
6. Improved design of an antigen with enhanced specificity for the broadly HIV-neutralizing antibody b12.
Pantophlet R; Wilson IA; Burton DR
Protein Eng Des Sel; 2004 Oct; 17(10):749-58. PubMed ID: 15542540
[TBL] [Abstract][Full Text] [Related]
7. Structural analysis of a highly glycosylated and unliganded gp120-based antigen using mass spectrometry.
Wang L; Qin Y; Ilchenko S; Bohon J; Shi W; Cho MW; Takamoto K; Chance MR
Biochemistry; 2010 Oct; 49(42):9032-45. PubMed ID: 20825246
[TBL] [Abstract][Full Text] [Related]
8. Roles of glycans in interactions between gp120 and HIV broadly neutralizing antibodies.
Qi Y; Jo S; Im W
Glycobiology; 2016 Mar; 26(3):251-60. PubMed ID: 26537503
[TBL] [Abstract][Full Text] [Related]
9. The glycan-mediated mechanism on the interactions of gp120 with CD4 and antibody: Insights from molecular dynamics simulation.
Zhang Y; Niu Y; Tian J; Liu X; Yao X; Liu H
Chem Biol Drug Des; 2017 Dec; 90(6):1237-1246. PubMed ID: 28632942
[TBL] [Abstract][Full Text] [Related]
10. [Role of the HIV-1 gp120 V1/V2 domains in the induction of neutralizing antibodies].
Granados-González V; Piedrahita LD; Martínez M; Genin C; Riffard S; Urcuqui-Inchima S
Enferm Infecc Microbiol Clin; 2009 Nov; 27(9):523-30. PubMed ID: 19409660
[TBL] [Abstract][Full Text] [Related]
11. Free Energy Perturbation Calculation of Relative Binding Free Energy between Broadly Neutralizing Antibodies and the gp120 Glycoprotein of HIV-1.
Clark AJ; Gindin T; Zhang B; Wang L; Abel R; Murret CS; Xu F; Bao A; Lu NJ; Zhou T; Kwong PD; Shapiro L; Honig B; Friesner RA
J Mol Biol; 2017 Apr; 429(7):930-947. PubMed ID: 27908641
[TBL] [Abstract][Full Text] [Related]
12. Computational discovery of novel HIV-1 entry inhibitors based on potent and broad neutralizing antibody VRC01.
Andrianov AM; Kashyn IA; Tuzikov AV
J Mol Graph Model; 2015 Sep; 61():262-71. PubMed ID: 26298811
[TBL] [Abstract][Full Text] [Related]
13. A mechanism by which binding of the broadly neutralizing antibody b12 unfolds the inner domain α1 helix in an engineered HIV-1 gp120.
Emileh A; Abrams CF
Proteins; 2011 Feb; 79(2):537-46. PubMed ID: 21117239
[TBL] [Abstract][Full Text] [Related]
14. The antigenic structure of the HIV gp120 envelope glycoprotein.
Wyatt R; Kwong PD; Desjardins E; Sweet RW; Robinson J; Hendrickson WA; Sodroski JG
Nature; 1998 Jun; 393(6686):705-11. PubMed ID: 9641684
[TBL] [Abstract][Full Text] [Related]
15. Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design.
Saphire EO; Parren PW; Pantophlet R; Zwick MB; Morris GM; Rudd PM; Dwek RA; Stanfield RL; Burton DR; Wilson IA
Science; 2001 Aug; 293(5532):1155-9. PubMed ID: 11498595
[TBL] [Abstract][Full Text] [Related]
16. Crystal structure of a 3B3 variant--a broadly neutralizing HIV-1 scFv antibody.
Clark KR; Walsh ST
Protein Sci; 2009 Dec; 18(12):2429-41. PubMed ID: 19785005
[TBL] [Abstract][Full Text] [Related]
17. AIDS/HIV. Converging on an HIV vaccine.
Korber B; Gnanakaran S
Science; 2011 Sep; 333(6049):1589-90. PubMed ID: 21921189
[No Abstract] [Full Text] [Related]
18. Metabolic labeling of HIV-1 envelope glycoprotein gp120 to elucidate the effect of gp120 glycosylation on antigen uptake.
Sun L; Ishihara M; Middleton DR; Tiemeyer M; Avci FY
J Biol Chem; 2018 Sep; 293(39):15178-15194. PubMed ID: 30115684
[TBL] [Abstract][Full Text] [Related]
19. Importance of conformation on the neutralizing antibody response to HIV-1 gp120.
Steimer KS; Haigwood NL
Biotechnol Ther; 1991; 2(1-2):63-89. PubMed ID: 1726963
[TBL] [Abstract][Full Text] [Related]
20. Towards a structure of the HIV-1 envelope glycoprotein gp120: an immunochemical approach.
Moore JP; Jameson BA; Sattentau QJ; Willey R; Sodroski J
Philos Trans R Soc Lond B Biol Sci; 1993 Oct; 342(1299):83-8. PubMed ID: 7904352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
